|
|
|
|
||
 |
 |
 |
 |
 |
 |
 |
 |
Board of Directors
David F. Hale is one of our co-founders and has served as Executive Chairman of our Board of Directors since December 2007. Mr. Hale served as our Interim CEO from January 2008 to August 2008 and as Non-Executive Chairman of our Board from August 2003 to December 2007. Mr. Hale is Chairman and Chief Executive Officer of Hale BioPharma Ventures. He served as President and Chief Executive Officer and a director of CancerVax Corporation, from October 2000 through its merger with Micromet, Inc., in 2006 where he became Chairman. He was President and Chief Executive Officer and a director of Women First HealthCare, Inc., from January 1998 to May 2000. Mr. Hale served as President, Chief Executive Officer, Chairman and a director of Gensia Inc., which merged to become Gensia Sicor, from May 1987 to November 1997. Prior to joining Gensia, Mr. Hale was President and Chief Executive Officer and a director of Hybritech, Inc., and previously held sales, marketing and general management positions with Johnson & Johnson and Becton Dickinson. Mr. Hale serves as Chairman of the boards of directors of Santarus, Inc., and SkinMedica, Inc., specialty pharmaceutical companies, and Metabasis Therapeutics, Inc., a biopharmaceutical company. He also serves as a director of privately-held biotechnology and specialty pharmaceutical companies including Verus Pharmaceuticals, Inc., and Conatus Pharmaceuticals. Mr. Hale is also a co-founder and member of the boards of directors of industry organizations including BIOCOM/San Diego, the California Healthcare Institute, and CONNECT and is a member of the boards of directors of the Biotechnology Industry Organization and Rady Children's Hospital, the San Diego Economic Development Corporation, and the Biotechnology Institute. Mr. Hale received a Bachelor of Arts degree in Biology and Chemistry from Jacksonville State University. Richard W. Pascoe joined Somaxon as our President and Chief Executive Officer in August 2008. Before joining Somaxon, Mr. Pascoe was the Chief Operating Officer at ARIAD Pharmaceuticals, an emerging oncology company, where he led commercial operations, manufacturing, information services, program and alliance management and business development. Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., including senior vice president of neuroscience marketing and sales and vice president positions in both international sales and marketing and hospital sales. He also held positions in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc. (where he helped lead the successful launch of eptifibatide [Integrilin®]), B. Braun Interventional and the BOC Group. Mr. Pascoe served as a commissioned officer in the United States Army following his graduation from the United States Military Academy at West Point where he received a B.S degree in Leadership.
Michael L. Eagle has served on our board of directors since May of 2007. He served as Vice President of Manufacturing for Eli Lilly and Company from 1994 through 2001 and held a number of executive management positions with Eli Lilly and its subsidiaries throughout his career there. Mr. Eagle serves as chairman of the board of directors of Favrille, Inc., and serves on the boards of directors of Micrus Endovascular Corporation, XTENT, Inc, and a number of privately-held companies. Mr. Eagle earned a Bachelor of Science degree in mechanical engineering from Kettering University and an MBA from the Krannert School of Management at Purdue University . He serves on the Board of Trustees of Kettering University, on the Dean's Senior Advisory Council of the Krannert School of Management at Purdue University. Erle T. Mast has served on our board of directors since June 2008. Mr. Mast was Chief Financial Officer of Pharmion Corporation from 2002 until its acquisition by Celgene Corporation in March 2008. Mr. Mast was also an Executive Vice President of Pharmion from February 2006 until the acquisition. He was Vice President of Finance for Dura Pharmaceuticals, Inc. from 1997 until its acquisition by Elan Corporation, plc in 2000, and thereafter he was Chief Financial Officer of Elan's Global Biopharmaceuticals business until 2002. Prior to that, Mr. Mast was a partner with Deloitte & Touche, LLP. Mr. Mast graduated from California State University Bakersfield with a degree in business administration.
Thomas G. Wiggans has served on our board of directors since June 2008. Mr. Wiggans served as Chief Executive Officer of Connetics Corporation from 1994 until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. Mr. Wiggans was also Chairman of the Board of Connetics from January 2006 until the acquisition. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc. He served in various positions at Ares-Serono Group from 1980 to 1992, including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans currently serves as Chairman of the Board of Peplin, Inc. and on the board of directors of Sangamo Biosciences, Inc. and Onyx Pharmaceuticals, Inc. He is also on the Board of Overseers of the Hoover Institution at Stanford University and the Board of Trustees of the University of Kansas Endowment Association . In addition, Mr. Wiggans is Chairman of the Biotechnology Institute, a non-profit educational organization. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
|